Innovation Pharmaceuticals Inc. (IPIX) Research

Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions. The company's lead drug candidate, Brilacidin, is currently in development for treating oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Furthermore, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound being investigated for ovarian cancer. The company holds a license agreement with Alfasigma S.p.A. and has a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. Established in 2005 and headquartered in Wakefield, Massachusetts, the firm operated as Cellceutix Corporation until its name change to Innovation Pharmaceuticals Inc. in June 2017.

Market snapshot

Symbol
IPIX
Price
$0.00
Day change
0.00%
Market cap
$155.5K
P/E ratio
-0.05x
52-week range
0.00001-0.05
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • ChitogenX Inc. (CHNXF)
  • Lift & Co. Corp. (LFCOF)
  • MedGen, Inc. (MDIN)
  • Nascent Biotech, Inc. (NBIO)
  • Actavia Life Sciences, Inc. (RASP)
  • RegeneRx Biopharmaceuticals, Inc. (RGRX)
  • RespireRx Pharmaceuticals Inc. (RSPI)
  • Tevano Systems Holdings Inc. (TEVNF)

Recent insider activity

  • EHRLICH LEO — J-Other (11307527 shares) on 2022-12-30
  • Harness Jane A. — A-Award (500000 shares) on 2021-10-10
  • Harness Jane A. — A-Award (58394 shares) on 2020-09-11
  • Harness Jane A. — A-Award (58394 shares) on 2019-09-01
  • Harness Jane A. — F-InKind (21606 shares) on 2020-09-11

Open Innovation Pharmaceuticals Inc. (IPIX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.